Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
Study published in JAMA Network Open of over 193,000 patients nationwide reveals that individuals with evidence of exposure to Borrelia burgdorferi, the bacterium that causes Lyme disease, are more than four times as likely to have antibodies against other tick-borne pathogens compared to...
Covered in this story
What has happened since
- Quest Diagnostics is down 3.8% since this was published, 29 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Quest Diagnostics
- Truist Securities: $228 → $250 by Jul 2027 · Hold via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $DGX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Quest Diagnostics →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.